N-Acetyl-D-Glucosamine (NAG, CAS 7512-17-6) is the acetylated amide derivative of D-glucosamine and the rate-limiting monosaccharide substrate for endogenous hyaluronic acid (HA) biosynthesis in human skin. The complete biosynthetic pathway: NAG is phosphorylated by N-acetylglucosamine kinase (NAGK) to NAG-6-phosphate, isomerized by phosphoacetylglucosamine mutase (PGM3) to NAG-1-phosphate, then converted by UDP-N-acetylglucosamine pyrophosphorylase 1 (UAP1) to UDP-GlcNAc — the activated nucleotide sugar donor. UDP-GlcNAc is then polymerized into hyaluronic acid by HA synthase (HAS1/2/3) at the plasma membrane. NAG is the rate-limiting step: without sufficient NAG substrate, UDP-GlcNAc pools are depleted and HA synthesis stalls regardless of HAS enzyme expression levels. Clinical trial data demonstrate that oral and topical NAG supplementation increases dermal HA content by 15–30%. UPOR Biotech produces NAG via fermentation-derived enzymatic acetylation of glucosamine (from chitin using Aspergillus niger chitinase), yielding a natural, bioidentical product.

The 4% NAG + 4% niacinamide combination is a clinically validated, FDA-recognized hyperpigmentation treatment (Procter & Gamble patent) that targets two distinct control points in melanogenesis for synergistic efficacy. (1) NAG inhibits tyrosinase glycosylation — tyrosinase requires post-translational N-linked glycosylation in the ER/Golgi to fold into its active conformation and reach the melanosome membrane. NAG competitively interferes with this essential glycosylation step, reducing the pool of mature, catalytically active tyrosinase enzyme without cytotoxicity or melanocyte damage. (2) Niacinamide inhibits melanosome transfer from melanocytes to keratinocytes via PAR-2 receptor antagonism — a completely separate, downstream control point that blocks pigment distribution rather than pigment synthesis. Together, these two non-overlapping mechanisms provide comprehensive hyperpigmentation efficacy comparable to hydroquinone but with an exemplary long-term safety profile. This combination is compatible with all Fitzpatrick skin types I–VI, including darker tones most prone to PIH, and is suitable for long-term daily use without cycling or pulse-therapy. The P&G patent has established this as a clinically credible, dermatologist-recommended non-hydroquinone treatment standard.

Cosmetic usage rate: 2–5% in leave-on formulations. The 4% concentration is clinically validated for hyperpigmentation (in combination with 4% niacinamide) and HA biosynthesis stimulation. NAG is water-soluble (~50 mg/mL at 25°C) — add to the aqueous phase with gentle heating (40–50°C) for faster dissolution; no co-solvents or pre-dissolution steps required. pH stable from 4–8; compatible with niacinamide, vitamin C (L-ascorbic acid), peptides, AHAs, BHAs, retinol, and virtually all standard cosmetic ingredients. For nutraceutical formulations: 250–1500 mg per day orally, typically delivered in capsules or tablets. NAG is well-tolerated orally with an excellent gastrointestinal safety profile. The dual cosmetic + nutraceutical positioning enables inside-out HA product strategies — topical NAG for dermal HA stimulation combined with oral NAG for systemic HA support including joint health. Always pair brightening formulations with daily broad-spectrum sunscreen for optimal hyperpigmentation results.

NAG occupies a unique position in the HA precursor hierarchy that glucosamine, hyaluronic acid, and other HA-boosting ingredients cannot replicate. Glucosamine (non-acetylated) must first be acetylated intracellularly by glucosamine-6-phosphate N-acetyltransferase (GNPNAT1) to enter the UDP-GlcNAc pathway — this intracellular acetylation step is a rate-limiting bottleneck because GNPNAT1 activity is finite, and unacetylated glucosamine can accumulate without contributing to HA synthesis. NAG bypasses this bottleneck entirely as the pre-acetylated, pathway-ready substrate. Hyaluronic Acid (topical or oral) is a finished high-molecular-weight polymer (1.0–1.8 MDa) that cells cannot directly reuse for endogenous HA synthesis — it must undergo extracellular degradation to monosaccharides, cellular uptake, re-phosphorylation, and re-polymerization, an energetically wasteful catabolic-anabolic cycle. NAG delivers the direct monomeric building block at the pathway entry point. Other HA-boosting actives (e.g., calcium ketogluconate) stimulate HAS gene expression but address the “enzyme abundance” side — they cannot compensate for substrate shortage. NAG addresses the “substrate availability” root cause. The optimal dual strategy: NAG (rate-limiting substrate) + calcium ketogluconate (HAS expression upregulator) — supplying the building block while stimulating the polymerase. For hyperpigmentation, NAG offers unique dual functionality — HA precursor + tyrosinase glycosylation inhibitor — a combination no other HA-boosting ingredient provides.

Every shipment includes: COA (HPLC purity ≥99.0% cosmetic/nutraceutical or ≥98.0% standard, full impurity profile including glucosamine free base ≤0.5%, chloride content ≤0.05%, acetyl content 18.5–19.5% w/w, heavy metals ≤10 ppm with Pb ≤2 ppm / As ≤1 ppm / Hg ≤1 ppm / Cd ≤1 ppm, residual solvents per USP <467> / EP <5.4> / ICH Q3C, microbial panel per USP <61>/<62> and EP <2.6.12>/<2.6.13>), MSDS, HPLC Chromatogram (signed and dated), Specific Rotation Certificate ([α]D²⁰ +39.0° to +42.0°), Melting Point Determination (196–205°C), BSE/TSE-Free Statement, Non-GMO Statement, Allergen Statement, HALAL Certificate, KOSHER Certificate, ISO 22000 + HACCP, ISO 9001:2015, FDA Facility Registration, Stability Data (25°C/60%RH real-time 36-month and 40°C/75%RH accelerated 6-month), and Complete Lot Traceability from chitin raw material through Aspergillus niger enzymatic hydrolysis and chemical acetylation to finished NAG product. Fermentation process documentation including chitinase enzyme specification and acetylation batch records available upon request. Free sample available for qualified B2B buyers. MOQ: 1 kg. All documents provided in English.